Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc. have finalised an exclusive distribution and reseller agreement covering Virotek's ophthalmology genomic testing and screening programme in the United States.
Under the agreement, which took effect on September 4, 2026, Kala will serve as the sole U.S. distributor of the programme and will have the right to market, promote, distribute and resell Virotek's ophthalmology genetic testing services.
The agreement has an initial one-year term, with continued exclusivity dependent on Kala achieving agreed commercial milestones. It follows a non-binding letter of intent announced on September 1, 2026.
Virotek will remain responsible for the programme's infrastructure, supply of testing kits, specimen processing and clinical reporting. The company will also provide training and supporting materials to Kala's channel partners.
The companies have agreed to a profit-sharing arrangement that will take effect after Virotek recovers its programme costs. No additional financial terms were disclosed.
#programme
Under the agreement, which took effect on September 4, 2026, Kala will serve as the sole U.S. distributor of the programme and will have the right to market, promote, distribute and resell Virotek's ophthalmology genetic testing services.
The agreement has an initial one-year term, with continued exclusivity dependent on Kala achieving agreed commercial milestones. It follows a non-binding letter of intent announced on September 1, 2026.
Virotek will remain responsible for the programme's infrastructure, supply of testing kits, specimen processing and clinical reporting. The company will also provide training and supporting materials to Kala's channel partners.
The companies have agreed to a profit-sharing arrangement that will take effect after Virotek recovers its programme costs. No additional financial terms were disclosed.
#programme
3 days ago
